AGMB

AgomAb Therapeutics NV

• Seeking Alpha·5d ago

  AgomAb Therapeutics: High Risk, High Reward Stock

• TipRanks·05/27 11:28

  Agomab Shareholders Approve All 2025 Accounts and Board Reappointments at May 26 AGM

• PUBT·05/27 09:00

  Agomab Therapeutics holds annual general meeting, backs board reappointments

• TipRanks·05/18 13:01

  Wall Street Analysts Are Bullish on Top NA Picks

• TipRanks·04/24 20:47

  Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones

• Seeking Alpha·04/24 12:41

  AgomAb Therapeutics NV reports FY results

• PUBT·04/23 21:18

  Agomab FY25 net loss widens 35% to EUR 62.5 million

• TipRanks·03/26 11:31

  Agomab receives U.S. patent for AGMB-447

• Reuters·03/26 11:02

  AGOMAB RECEIVES U.S. PATENT FOR AGMB-447, ITS INHALED LUNG-RESTRICTED SMALL MOLECULE INHIBITOR OF ALK5 IN DEVELOPMENT FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

• Reuters·03/26 11:01

  Agomab Therapeutics receives U.S. Patent No. 12,577,230 for AGMB-447; IP protection extends through at least 2041

• Reuters·03/18 20:03

  Agomab Therapeutics NV Director David R Epstein Files Initial Beneficial Ownership Statement

• Reuters·03/18 20:03

  Agomab Therapeutics NV CFO Kemula Pierre Thadee Victor files Form 3 initial beneficial ownership statement

• Reuters·03/18 20:03

  Agomab Therapeutics NV CEO and Director Tim Jasper Knotnerus Files Initial Beneficial Ownership Statement

• Reuters·03/18 20:02

  Agomab Therapeutics NV Director Ohad Hammer files initial beneficial ownership statement

• Reuters·03/18 20:02

  Agomab Therapeutics NV director Colin Michael Bond files Form 3 initial beneficial ownership statement